Trial | NCT01328392  Report issue

Official Title

Evaluating Treatment Response in Laryngo-Pharyngeal Reflux

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Study Participants

    0
Although laryno-pharyngeal reflux (LPR) and gastroesophageal reflux disease (GERD) differ in symptoms and treatment, they are diagnosed by the same standard 24-hour pH monitoring system which measures liquid reflux in the esophagus. The investigators are evaluating a new 24-hour pharyngeal pH monitoring system by Restech which can measure acid exposure in the airway and can be used specifically for LPR diagnosis. The purpose of this study is to determine whether the Restech device is more effective than standard pH monitoring in predicting the response to proton pump inhibitor (PPI) acid suppression therapy using Dexlansoprazole in patients with symptoms and/or manifestations of LPR.
Study Started
May 31
2011
Primary Completion
Apr 30
2012
Anticipated
Study Completion
Apr 30
2012
Anticipated
Last Update
Jul 05
2017

Drug Dexlansoprazole

30mg a day, 3 months

  • Other names: Dexilant

Criteria 

Inclusion Criteria:

Age 18 years old or above
Have a clinical diagnosis of LPR
Able and willing to provide consent

Exclusion Criteria:

History of any previous anti-reflux operation or procedure
History of pharyngeal or laryngeal surgery
History of larngeal or hypolaryngeal neoplasm
Allergy or significant adverse reaction to PPI
Patient on PPI therapy within 4 weeks prior to enrollment
A cumulative history of PPI therapy equal to or greater than 3 months
History of noncompliance with medication or study protocols
Enrolled in another clinical trial using investigational medications
No Results Posted